Description

Product details

CINASELECT 60: Comprehensive Guide to Cinacalcet 60 mg Tablets Product Overview CINASELECT 60 is a pharmaceutical formulation containing Cinacalcet hydrochloride 60 mg as its active ingredient. This medication represents a significant advancement in the management of calcium metabolism disorders, particularly in patients with chronic kidney disease and parathyroid conditions. As a calcimimetic agent, CINASELECT 60 works by mimicking the action of calcium on tissues, helping to restore hormonal balance and mineral homeostasis in the body. The 60 mg dosage strength offers an effective therapeutic option for patients requiring moderate to higher-level intervention in managing parathyroid hormone levels and associated calcium imbalances. CINASELECT 60 is manufactured under strict quality control standards, ensuring consistency, purity, and efficacy in every tablet. Understanding How CINASELECT 60 Works CINASELECT 60 operates through a sophisticated mechanism that targets the calcium-sensing receptors located on the surface of parathyroid gland cells. These receptors play a crucial role in regulating parathyroid hormone secretion, which in turn controls calcium and phosphorus levels in the bloodstream. When you take CINASELECT 60, the active ingredient cinacalcet binds to these calcium-sensing receptors, increasing their sensitivity to extracellular calcium. This enhanced sensitivity tricks the parathyroid glands into “thinking” there is more calcium present in the blood than there actually is. As a result, the glands reduce their production and release of parathyroid hormone (PTH). By lowering PTH levels, CINASELECT 60 subsequently reduces calcium levels in the blood and decreases the amount of phosphorus absorbed from the intestines. This cascade effect helps restore the delicate mineral balance that is often disrupted in patients with kidney disease or parathyroid disorders. Primary Therapeutic Uses Secondary Hyperparathyroidism in Chronic Kidney Disease The primary indication for CINASELECT 60 is the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) who are on dialysis. When kidneys fail to function properly, they cannot adequately regulate calcium and phosphorus levels, leading to excessive parathyroid hormone production. This condition can result in serious complications including bone disease, cardiovascular calcification, and increased mortality risk. CINASELECT 60 helps manage this condition by controlling PTH levels, thereby reducing the risk of bone complications such as osteitis fibrosa cystica and preventing the dangerous deposition of calcium in blood vessels and soft tissues. Hypercalcemia in Parathyroid Carcinoma CINASELECT 60 is also indicated for treating hypercalcemia (elevated blood calcium levels) in patients with parathyroid carcinoma, a rare malignant tumor of the parathyroid glands. In these cases, the medication helps control the dangerously high calcium levels that can lead to kidney stones, bone pain, digestive issues, and neurological symptoms. Primary Hyperparathyroidism For patients with severe hypercalcemia due to primary hyperparathyroidism who cannot undergo parathyroidectomy or for whom surgery has failed, CINASELECT 60 offers a valuable medical management option. This provides relief for patients who are not surgical candidates due to advanced age, comorbidities, or other contraindications. Key Benefits of CINASELECT 60 Effective PTH Control Clinical studies have demonstrated that CINASELECT 60 significantly reduces parathyroid hormone levels in a dose-dependent manner. This reduction helps prevent the cascade of complications associated with elevated PTH, including bone mineral loss and cardiovascular calcification. Improved Calcium-Phosphorus Balance By reducing PTH secretion, CINASELECT 60 helps normalize serum calcium and phosphorus levels. This is particularly important in dialysis patients, where mineral imbalances can lead to serious complications affecting bone health, cardiovascular function, and overall quality of life. Reduced Cardiovascular Risk Elevated calcium and phosphorus levels contribute to vascular calcification, a major risk factor for cardiovascular disease in patients with chronic kidney disease. By managing these mineral levels, CINASELECT 60 may help reduce the risk of cardiovascular complications, which are the leading cause of death in dialysis patients. Bone Health Preservation Uncontrolled secondary hyperparathyroidism leads to renal osteodystrophy, a condition characterized by abnormal bone metabolism. CINASELECT 60 helps protect bone integrity by normalizing PTH levels, potentially reducing fracture risk and preserving bone mineral density. Alternative to Surgery For patients with primary hyperparathyroidism or parathyroid carcinoma who cannot undergo surgery, CINASELECT 60 provides an effective medical management option. This is particularly valuable for elderly patients or those with multiple comorbidities that make surgery risky. Quality of Life Improvement By controlling symptoms associated with hypercalcemia and hyperparathyroidism, such as bone pain, muscle weakness, fatigue, and digestive issues, CINASELECT 60 can significantly improve patients' overall quality of life and functional capacity. Convenient Oral Administration CINASELECT 60 is administered orally, making it more convenient than injectable alternatives. This allows for outpatient management and reduces the burden on healthcare facilities and patients. Potential Side Effects and Adverse Reactions Common Side Effects Patients taking CINASELECT 60 may experience several common side effects, which typically include nausea and vomiting, occurring in approximately 20-30% of patients. These gastrointestinal symptoms are usually mild to moderate and may improve over time as the body adjusts to the medication. Diarrhea is another frequent complaint, affecting roughly 20% of users. Some patients also report muscle pain or myalgia, dizziness, loss of appetite, and asthenia (general weakness or fatigue). Serious Side Effects Requiring Medical Attention Hypocalcemia: The most significant risk associated with CINASELECT 60 is the development of low calcium levels in the blood. Severe hypocalcemia can lead to paresthesias (tingling sensations), muscle cramps or spasms, tetany, seizures, and QT interval prolongation on electrocardiogram, which can predispose to dangerous heart rhythm abnormalities. Gastrointestinal Bleeding: There have been reports of gastrointestinal hemorrhage in patients taking cinacalcet, particularly in those with risk factors such as gastritis, ulcers, or concurrent use of other medications that increase bleeding risk. Adynamic Bone Disease: Oversuppression of PTH can lead to adynamic bone disease, a condition where bone turnover becomes abnormally low, potentially weakening bones despite normalized calcium levels. Cardiovascular Effects: Some patients may experience worsening heart failure or arrhythmias, particularly if hypocalcemia develops. Close monitoring is essential in patients with underlying cardiovascular disease. Allergic Reactions: Though rare, hypersensitivity reactions including rash, urticaria, and angioedema have been reported. Precautions and Contraindications CINASELECT 60 should not be used in patients with serum calcium levels below the normal range. It requires careful dose adjustment and monitoring in patients with hepatic impairment. The medication may interact with drugs metabolized by the CYP2D6 enzyme system and with medications that affect gastric pH. Pregnant or breastfeeding women should use CINASELECT 60 only if clearly needed, as its safety in these populations has not been fully established. Regular monitoring of serum calcium, phosphorus, and PTH levels is essential throughout treatment. Dosage and Administration Guidelines CINASELECT 60 should be taken orally with food or shortly after a meal, as this improves absorption and reduces gastrointestinal side effects. Tablets should be swallowed whole and not crushed, chewed, or divided. The typical starting dose for secondary hyperparathyroidism is lower than 60 mg, with gradual titration based on PTH and calcium levels. The 60 mg strength is often used as part of the dose escalation process or as a maintenance dose once optimal PTH control is achieved. Dose adjustments should be made no more frequently than every two to four weeks, as it takes this long to see the full effect of a dose change on PTH levels. Treatment should be individualized based on laboratory values and clinical response. Monitoring Requirements Patients on CINASELECT 60 require regular monitoring of serum calcium, phosphorus, and intact PTH levels. Calcium levels should be checked within one week of starting treatment or after any dose adjustment, and then monthly once stable. PTH levels should be measured one to four weeks after initiation or dose adjustment, then every one to three months during maintenance therapy. Additionally, patients should be monitored for signs and symptoms of hypocalcemia, particularly during the initial treatment period. Electrocardiogram monitoring may be appropriate in patients at risk for QT prolongation. Storage and Handling CINASELECT 60 should be stored at room temperature, away from moisture and direct sunlight. The medication should be kept in its original container with the lid tightly closed to protect from humidity. Keep out of reach of children and pets. Do not use past the expiration date printed on the package. Conclusion CINASELECT 60 (Cinacalcet 60 mg) represents a valuable therapeutic option in the management of secondary hyperparathyroidism associated with chronic kidney disease, hypercalcemia in parathyroid carcinoma, and primary hyperparathyroidism in patients who cannot undergo surgery. Its unique mechanism as a calcimimetic agent provides effective control of parathyroid hormone secretion, helping to restore mineral balance and prevent serious complications. The benefits of CINASELECT 60 extend beyond simple laboratory value normalization. By controlling PTH, calcium, and phosphorus levels, this medication helps preserve bone health, reduce cardiovascular calcification risk, and improve overall quality of life for patients dealing with complex metabolic disorders. For patients who are not surgical candidates, CINASELECT 60 offers hope and effective symptom management. However, like all medications, CINASELECT 60 must be used judiciously under close medical supervision. The risk of hypocalcemia and other potential side effects necessitates regular laboratory monitoring and open communication between patients and healthcare providers. Patients should report any concerning symptoms promptly and attend all scheduled follow-up appointments.

Other Specifications